Former AstraZeneca exec charged with insider trading in Daiichi Sankyo's licensing deal
U.S. · BUSINESS · SCIENCE
May 31, 20221 min read271 words
Published: May 31, 2022  |  1 min read271 words
Buying 500 shares of Daiichi Sankyo stock 16 days before the company signed a lucrative licensing deal with AstraZeneca has a former AZ executive in the Securities and Exchange Commission's (SEC's) crosshairs. According to an SEC complaint, Hugues Joublin, Ph.D.—who was AZ’s glo...
Former AstraZeneca exec charged with insider trading in Daiichi Sankyo's licensing deal Read more

No article scores yet.

There are no critic or public scores for this article yet.
Investigative2
critic reviews: 0
public reviews: 2
No reviews
img-contested
N/A
critic score
0 reviews
img-contested
N/A
public score
2 reviews
img-contested
N/A
critic score
0 reviews
img-contested
N/A
public score
2 reviews

CRITIC REVIEWS

There don't seem to be any reviews yet.

PUBLIC REVIEWS

Investigative
Jun 1
I am glad the people that have been charged with trying to take advantage of biopharma M&A activities with stock purchases are finally being exposed.
Jun 1
Is this helpful?
Investigative
Jun 1
This is just one of several examples of crooks trying to take advantage of biopharma M&A activities with stock purchases.
Jun 1
Is this helpful?